N/A N=253 Biologic Mesh Versus Synthetic Mesh in Repair of Ventral Hernias
Ventral Hernia
Primary: Number of Participants With Absence of Surgical Site Occurrence Requiring Procedural Intervention — 124; 126; 2; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Clinical and Radiological Evaluation of Patients With DDD Following TLIF With 3-D Printed Titanium Cage
Intervertebral Disc Disease
Primary: Fusion Rate — 19; 1; 0 Participants
N/A N=92 Neuronal and Behavioral Effects of Implicit Priming in Obese Individuals
Feeding Behavior · Obesity · Overweight
Primary: Change in Food Image Ratings — -5.1; -.3; -6.8; -2.7 Score change from baseline — p=0.038
N/A N=20 Evaluating Active Esophageal Cooling During Cardiac Ablation Procedures
Atrial Fibrillation
Primary: Total Time of Active Ablation Procedure — 3.26 Hours
N/A N=60 Clinical Comparison of Two Daily Disposable Contact Lenses - Pilot Study 3
Myopia · Ametropia
Primary: Distance VA (logMAR) With Study Lenses — -0.14; -0.15 logMAR
Phase 2 N=20 Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
Adenocarcinoma of the Esophagus · Adenocarcinoma of the Gastroesophageal Junction · Diffuse Adenocarcinoma of the Stomach
Primary: Disease-free Survival — 4 Participants
Phase 2 N=30 Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies
Epilepsy
Primary: Summary of 28-day Seizure Frequency for Sum of Individual Seizures and Clusters for 52-week OLE Period (Mean Percent Change & Standard Deviation) — -31.23; NA; 122.10…
Phase 2 N=11 A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601
Epilepsy, Complex Partial
Primary: Investigators Global Assessment — 6; 4; 0; 1 Participants
Phase 4 N=44 Pilot Study to Collect and Evaluate Data on the Use of IV* Ibuprofen in the Treatment of an Acute Migraine Attack
Episodic Migraine
Primary: Comparison of Proportion of Subjects in Control and Active Treatment Groups Who Have Pain Relief at 2 Hours After the Completion of the Double-blind Treatment Infusion…
Phase 2 N=18 Cannabidiol Treatment in Patients With Early Psychosis
Schizophrenia · Schizoaffective Disorder
Primary: Positive and Negative Syndrome Scale (PANSS) Over Time — 81.3; 84.0; 78.3; 75.3 score on a scale — p=0.08
N/A N=2,402 Enhancing Male Participation in Interventions to Prevent Unintended Pregnancy
Contraception
Primary: Number of Non-pregnant Couples With Modern Contraceptive Use in Past 3 Months — 265; 295 Couple
Phase 2 N=25 Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Primary: Number of Participants With Serious Adverse Events as Measured by Patient Reporting — 2 Participants
N/A N=96 Impact of a Virtual Diabetes Self-Care and Education Program on Diabetes-related Outcomes in Latinos With T2 Diabetes
Type 2 Diabetes Mellitus
Primary: Hemoglobin A1c — 8.41; 8.18 percentage of A1C
Phase 1 N=87 Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults
Polio
Primary: Number of Participants With Serious Adverse Events Over the Course of the Study — 0; 0; 0 Participants
N/A N=299 Primary Care Intervention to Reduce Prescription Opioid Overdoses
Pain · Drug Overdose · Opioid Use Disorders
Primary: Overdose Risk Behaviors — 1.31; 1.21; 1.45; 1.25 score on a scale